Current page location

Bioevaluation Center

Bio-evaluation Center
Objectives
Our aim is to establish a collective and specific infrastructure of techniques, facilities, and manpower to support the effective and successful development of biotech products. For this purpose, we have not only constructed developmental and evaluational infrastructure for optimizing, analyzing, and standardizing living modified organisms and drug candidates; but also assessed the usefulness and risks of biotech research and development processes and the biotech products themselves, to facilitate commercialization.
Researchers
researcher name and research fields
Name Research Fields
Soon-Chun Jeong
(Associate Director)
  • Molecular genetic characterization of LMOs
  • Soybean genomics
Chang-Gi Kim
  • Environmental risk assessment of LMOs
  • Plant ecology
Jung-Ho Park
  • Human risk assessment of LMOs
  • Protein engineering
Ju Seok Lee
  • Molecular genetic analysis of LMOs
  • Soybean population genetics
In-Soon Pack
  • Molecular genetic characterization of LMOs
research areas
  • Living modified organisms (LMOs)
    • Conducting genetic analysis and assessing the risks of LMOs
  • New drugs
    • Discovery and preclinical evaluation of new drug candidates
Achievements
  • Living modified organisms
    • We have established and developed infrastructure for genetic analysis and risk assessments of living modified organisms. In particular, we have been assessing the potential risks of domestically developed transgenic rices, chilli peppers, potatoes, poplars and rootstocks for watermelons. We also conduct National Environmental Monitoring on domestic soybeans, corns and oilseed rapes and the inspect the extent of genetic contamination by imported LMOs.
  • Drug discovery
    • We developed and implemented an integrated infrastructure for drug discovery encompassing preclinical efficacy, ADME and toxicity evaluations. We have applied this technology platform to the discovery and preclinical evaluation of drug candidates in the areas of cancer and immune-related diseases and supported drug discovery in the pharmaceutical industry, academia and research institutes.